Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336465 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT01336465 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 124 participants.
The verdict
NCT01336465, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
This Phase II study is a randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rhuMAb Beta7 in patients with moderate to severe ulcerative colitis.
Interventions
- DRUG placebo
- DRUG rhuMAb Beta7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01336465
The ClinicalTrials.gov registry entry for NCT01336465 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01336465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01336465 about?
NCT01336465 is a clinical study titled "Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis". This Phase II study is a randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rhuMAb Beta7 in patients with moderate to severe ulcerative colitis.
What is the current status of trial NCT01336465?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2011-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01336465?
The interventions under investigation include: placebo (DRUG), rhuMAb Beta7 (DRUG).
Who is sponsoring clinical trial NCT01336465?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.